Medicare AdvantageCoverageMedium impact
MA06.032a, Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing
Independence Blue Cross·Family Medicine, Internal Medicine, Endocrinology +1 more·Medical Policy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.032a for Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing has been reissued. This is a policy update that may affect coverage criteria, documentation requirements, or billing procedures for these laboratory tests under Medicare Advantage plans.
Action Required
By November 26, 2025: Billing team must review the complete MA06.032a policy at the source URL to understand specific changes to B12, folic acid, and homocysteine testing requirements. Update billing procedures and documentation requirements as specified in the full policy. Ensure staff are aware of any new coverage criteria or prior authorization requirements for these lab tests.